Importance Post–COVID-19 condition (PCC), also known as long COVID, affects many
individuals. Prevention of PCC is an urgent public health priority. Objective To examine …

Immunocompromised patients still experience unpredictable courses of COVID-19, despite
that effective vaccines and drugs against SARS-CoV-2 are now available. Antiviral …

This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …

The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the
treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of …

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …

Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …

An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID‐2019. In addition to the recommended …

On 4 th November 2021, the first oral antiviral drug for COVID-19, molnupiravir (Lagevrio®),
received full regulatory approval from the Medicines and Healthcare Products Regulatory …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …